Linfoma: Diretrizes Médicas (Lymphoma: Guidelines)

 

Laboratory workup of lymphoma in adults: guidelines from the American Society for Clinical Pathology and the College of American Pathologists

S H Kroft, C E Sever, A Bagg et al

Arch Pathol Lab Med 2021, vol 145 (3): 269-290

https://academic.oup.com/ajcp/article/155/1/12/5957527

 

Lymphoma: diagnosis and treatment

W D Lewis, S Lilly, K L Jones

American Family Physician 2020, vol 101 (1): 34-41

https://www.aafp.org/afp/2020/0101/p34.html

 

Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

S S Neelapu, S Adkins, S M Ansell et al

Journal of ImmunoTherapy 2020, vol 8 (2)

https://jitc.bmj.com/content/8/2/e001235

 

Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Sattva S Neelapu, Sherry Adkins, Stephen M Ansell, et al

J Immunother Cancer. 2020; 8(2): e001235

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768967/

 

Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)

Francisco-Javier Peñalver, Juan-Manuel Sancho, Adolfo de la Fuente et al

Haematologica. 2017 Feb; 102(2): 235–245

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286932/

 

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

  1. Younes, P. Hilden, B. Coiffier, A. Hagenbeek, G. Salles et al

Ann Oncol. 2017 Jul; 28(7): 1436–144

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834038/

 

Hodgkin lymphoma in adults: diagnosis, treatment, and follow-up

Paul J. Bröckelmann*, Dennis A. Eichenauer*, Tina Jakob et al

Dtsch Arztebl Int. 2018 Aug; 115(31-32): 535–540.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131364/

 

■  Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Data: março 2021

Trombocitopenia Induzida por Heparina: Diretrizes Médicas (Heparin Induced Thrombocytopenia: Guidelines)

– A trombocitopenia induzida por heparina é uma complicação grave da terapêutica anticoagulante com heparina e está associada à formação de anticorpos antifator IV plaquetário.

– Costuma surgir a partir do quinto dia do tratamento, com queda de pelo menos 50% da contagem plaquetária.

– Em decorrência da ativação plaquetária concomitante, pode ocorrer quadro de trombose, venosa ou arterial, com repercussões clínicas graves.

 

Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET)

Rossella Marcucci, Martina Berteotti, Anna M. Gori, et alBlood Transfus. 2021 Jan; 19(1): 14–23

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850929/

 

Management of heparin-induce thrombocytopenia: a systematic reviews and meta-analyses

Rebecca L. Morgan, Vahid Ashoorion, Adam Cuker et al

Blood Adv. 2020 Oct 27; 4(20): 5184–5193

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594379/

 

Heparin-induced thrombocytopenia in COVID-19

Prasanth Lingamaneni, Sriram Gonakoti, Krishna Moturi et al

J Investig Med High Impact Case Rep. 2020 Jan-Dec; 8: 2324709620944091

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388103/

 

Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management

M Hogan, J S Berger

Vascular Medicine March 2020

https://journals.sagepub.com/doi/full/10.1177/1358863X19898253

 

Heparin-induced thrombocytopenia in severe COVID-19

F Daviet, C Guervilly, O Baldesi et al

Circulation 2020, vol 142 (19)

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049015

 

■  Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Data: março 2021